Patent: 10,265,401
✉ Email this page to a colleague
Summary for Patent: 10,265,401
| Title: | Stable subcutaneous protein formulations and uses thereof |
| Abstract: | The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction. |
| Inventor(s): | Desai; Manisha P (Wayne, NJ), Dahlheim; Charles E (Lawrenceville, NJ), Borsadia; Sunita (Plainsboro, NJ), Naringrekar; Vijay H (Princeton, NJ), Gandhi; Rajesh Babulal (Plainsboro, NJ), Nerurkar; Manoj (Bellandur, IN) |
| Assignee: | BRISTOL-MYERS SQUIBB COMPANY (Princeton, NJ) |
| Application Number: | 15/066,480 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,265,401
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Llc | ZOSTAVAX | zoster vaccine live | For Injection | 125123 | May 25, 2006 | ⤷ Start Trial | 2036-03-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
